160 related articles for article (PubMed ID: 27129005)
1. Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Adkison KK; Jones LS; Lou Y; Gan J; Wilfret DA
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):338-45. PubMed ID: 27129005
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Gardner S; Cutrell A; Elko-Simms C; Adkison K; Hamatake R; Walker J; Rodriguez-Torres M; Hong Z
Liver Int; 2014 Jul; 34(6):e89-95. PubMed ID: 24107072
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
Wu J; Gießmann T; Lang B; Elgadi M; Huang F
J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.
Adkison KK; Gan J; Elko-Simms L; Gardner S; Dumont E; Jones LS; Saunders J; Marbury T; Smith W; Berg J; Galloway C; Stump PJ
J Clin Pharmacol; 2015 Sep; 55(9):1042-50. PubMed ID: 25857714
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans.
Shen J; Serby M; Surber B; Lee AJ; Ma J; Badri P; Menon R; Kavetskaia O; de Morais SM; Sydor J; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1148-57. PubMed ID: 27179128
[TBL] [Abstract][Full Text] [Related]
6. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1.
Wilfret DA; Walker J; Adkison KK; Jones LA; Lou Y; Gan J; Castellino S; Moseley CL; Horton J; de Serres M; Culp A; Goljer I; Spreen W
Antimicrob Agents Chemother; 2013 Oct; 57(10):5037-44. PubMed ID: 23896477
[TBL] [Abstract][Full Text] [Related]
8. Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
Polepally AR; Dutta S; Hu B; Podsadecki TJ; Awni WM; Menon RM
Clin Pharmacol Drug Dev; 2016 Jul; 5(4):269-77. PubMed ID: 27310328
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Wilfret DA; Walker J; Voitenleitner C; Baptiste-Brown S; Lovern M; Kim J; Adkison K; Shotwell B; Mathis A; Moss L; Lee D; Yu L; Gan J; Spaltenstein A
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):439-48. PubMed ID: 27129119
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.
Menon RM; Klein CE; Podsadecki TJ; Chiu YL; Dutta S; Awni WM
Br J Clin Pharmacol; 2016 May; 81(5):929-40. PubMed ID: 26710243
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.
Vince B; Hill JM; Lawitz EJ; O'Riordan W; Webster LR; Gruener DM; Mofsen RS; Murillo A; Donovan E; Chen J; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Zhou XJ
J Hepatol; 2014 May; 60(5):920-7. PubMed ID: 24434503
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.
Shen J; Serby M; Reed A; Lee AJ; Zhang X; Marsh K; Khatri A; Menon R; Kavetskaia O; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1164-73. PubMed ID: 27179127
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Menon RM; Badri PS; Wang T; Polepally AR; Zha J; Khatri A; Wang H; Hu B; Coakley EP; Podsadecki TJ; Awni WM; Dutta S
J Hepatol; 2015 Jul; 63(1):20-9. PubMed ID: 25646891
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
[TBL] [Abstract][Full Text] [Related]
17. Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.
Wilfret DA; Adkison KK; Jones LA; Lou Y; Gan J; Spreen W
Antimicrob Agents Chemother; 2013 Oct; 57(10):5141-3. PubMed ID: 23856771
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Khatri A; Menon RM; Marbury TC; Lawitz EJ; Podsadecki TJ; Mullally VM; Ding B; Awni WM; Bernstein BM; Dutta S
J Hepatol; 2015 Oct; 63(4):805-12. PubMed ID: 26070406
[TBL] [Abstract][Full Text] [Related]
19. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
[TBL] [Abstract][Full Text] [Related]
20. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
de Kanter CT; Colbers AP; Blonk MI; Verweij-van Wissen CP; Schouwenberg BJ; Drenth JP; Burger DM
J Antimicrob Chemother; 2013 Jun; 68(6):1415-22. PubMed ID: 23429642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
